Roche Removes a Blemish: Drugmaker Drops Its One-Time Acne Blockbuster Accutane
This article was originally published in The Pink Sheet Daily
Executive Summary
Holding less than 5 percent of isotretinoin market and burdened with the costs of personal injury suits, Roche decides to discontinue its acne drug.
You may also be interested in...
US FDA Asks Manufacturers To Fix Disruption In Isotretinoin REMS
The agency offers ‘regulatory flexibility’ for certain requirements of the iPLEDGE REMS for the acne drug if manufacturers address delays in implementing the modified program.
DTC Advertising For ADHD, Acne, Antidepressant Meds Could Shift After FDA Study
Seeking to better understand how adolescents process information in direct-to-consumer ads, agency proposes survey using web-based promotions for fictitious treatments.
REMS Refinement: Does iPLEDGE’s Evolution Have Lessons For Opioids?
The Drug Safety and Risk Management and Dermatologic and Ophthalmic Drugs Advisory Committees will assess the risk management program Dec. 1 for lessons about implementing REMS containing elements to assure safe use and selecting assessment metrics.